Berenberg Bank Reiterates "Hold" Rating for Eli Lilly and Company (NYSE:LLY)

Key Points

• Berenberg Bank has reiterated a "hold" rating for Eli Lilly and Company, reducing its price target from $970.00 to $830.00, which indicates a potential upside of 8.70% from the current price.
• Analysts have mixed ratings on Eli Lilly, with one having a Strong Buy rating, fourteen rating it as Buy, and nine as Hold, leading to an overall consensus rating of "Moderate Buy".
• Eli Lilly's recent quarterly earnings showed a significant beat of analyst expectations, reporting $6.31 earnings per share (EPS) on revenues of $15.56 billion.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock had its "hold" rating reiterated by Berenberg Bank in a research note issued to investors on Wednesday, Marketbeat.com reports. They presently have a $830.00 price objective on the stock, down from their prior price objective of $970.00. Berenberg Bank's price objective would suggest a potential upside of 8.70% from the stock's current price.

A number of other research firms have also issued reports on LLY. Guggenheim dropped their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating for the company in a research report on Wednesday, August 13th. Daiwa America lowered Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Erste Group Bank lowered Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $763.59 on Wednesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a 50 day moving average of $740.25 and a two-hundred day moving average of $774.23. The firm has a market cap of $722.71 billion, a P/E ratio of 49.91, a price-to-earnings-growth ratio of 1.04 and a beta of 0.47. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $939.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president owned 137,660 shares in the company, valued at $87,331,504. The trade was a 0.73% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jamere Jackson acquired 200 shares of the stock in a transaction dated Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Brighton Jones LLC increased its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares in the last quarter. Orion Capital Management LLC increased its position in shares of Eli Lilly and Company by 2.5% during the fourth quarter. Orion Capital Management LLC now owns 1,610 shares of the company's stock worth $1,243,000 after purchasing an additional 40 shares in the last quarter. Bank Pictet & Cie Europe AG increased its position in shares of Eli Lilly and Company by 4.1% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company's stock worth $49,993,000 after purchasing an additional 2,568 shares in the last quarter. Finally, Breed s Hill Capital LLC increased its position in shares of Eli Lilly and Company by 212.0% during the fourth quarter. Breed s Hill Capital LLC now owns 1,426 shares of the company's stock worth $1,101,000 after purchasing an additional 969 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.